A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100™ and its predictors

Platelets

Volumn 17, Issue 1, 2006, Pages 7-13

  Abaci, Adnan ^a   Caliskan, Mustafa ^b   Bayram, Fahri ^b   Yilmaz, Yucel ^b   Cetin, Mustafa ^b   Unal, Ali ^b   Cetin, Servet ^b  

^a GAZI UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Aspirin; Function; Non responsiveness; Platelet

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; STANDARDIZATION; THROMBOCYTE FUNCTION;

ASPIRIN; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DIET; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 28744450414     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500163358     Document Type: Article

References (25)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
2. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;63:587-593.
3. Helgason CM, Tortorice KL, Winkler ER, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
4. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336.
5. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston CM. Results of the BRAT study - A pilot study investigating the possible significance of ASA non-responsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000;16:1385-1390.
6. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
8. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency od aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002;90:893-895.
9. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet P1A1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 2003;42:1115-1119.
10. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the ultegra rapid platelet function assay-ASA. Am J Cardiol 2003;92:1492-1494.
11. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42.
12. Chen WH, Lee PY, Ng W, Tse HT, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment. J Am Coll Cardiol 2004;43:1122-1126.
13. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
14. Kundu SK, Heilman EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb Hemost 1996;2:241-249.
15. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
16. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Spelser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost. 2000;83:316-321.
17. Serebruany VL, Alford AB, Meister AF et al. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). Thromb Res 2001;101:427-433.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1202.
19. Mammen EF, Alshameri RS, Comp PC. Preliminary data from a field trial of the PFA-100™ system. Semin Thromb Hemostas 1995;21(Suppl 2):113-121.
20. Cox D. Methods for monitoring platelet function. Am Heart J 1998;135:S160-S169.
21. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003;41:966-968.
22. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-S178.
23. Coppe D, Wessinger SJ, Ransil BJ, Harris W, Salzman E. Sex differences in the platelet response to aspirin. Thromb Res 1981;23:1-21.
24. De la Cruz JP, Bellido I, Camara S, Martos F, Sanchez de la Cuesta F. Effects od acetylsalicylic acid on platelet aggregation in male and female whole blood: An in vitro study. Scandinavian J Haematol 1986;36:394-397.
25. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100™ closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 2004;124:80-85.